Identifying host biomarkers that determine susceptibility to colonization with an emerging fungal pathogen Candida auris.

This study is a part of Multi-Center application in response to the CDC # RFA-CK-20-004. Emerging infectious diseases pose a critical risk to human health. The fungal pathogen Candida auris is a globally emerging pathogen of humans, and has been isolated from nosocomial infections acquired in five continents (Asia, Africa, Europe, South America and North America). Clinically isolated C. auris strains are often resistant to antifungals, thus treatment options are limited in the clinical setting. Overall, we have a limited understanding of the colonization and virulence strategies employed by C. auris and the environmental settings that promote C. auris colonization and pathogenesis. However, it is well documented that the human skin can be colonized by C. auris. Intriguingly, C. auris colonization can remain asymptomatic in some people for unknown reasons. We hypothesize that human skin microbiome may play a role in controlling C. auris colonization. In the U.S. there have been about 1000 reported cases of C. auris infection in a hospital setting (CDC website). As stated by CDC, the highest number of cases have been reported from the states of New York (461 cases), Illinois (288 cases) and New Jersey (155 cases). In this project, we will partner with J. Craig Venter Institute to investigate risk factors associated with C. auris colonization.